Avalon Trust Co Decreases Holdings in The Cooper Companies, Inc. $COO

Avalon Trust Co lowered its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 97.6% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,960 shares of the medical device company’s stock after selling 202,070 shares during the period. Avalon Trust Co’s holdings in Cooper Companies were worth $340,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. CYBER HORNET ETFs LLC acquired a new stake in Cooper Companies in the 2nd quarter worth about $36,000. MUFG Securities EMEA plc purchased a new position in shares of Cooper Companies in the second quarter valued at approximately $42,000. Assetmark Inc. boosted its stake in shares of Cooper Companies by 357.8% in the second quarter. Assetmark Inc. now owns 618 shares of the medical device company’s stock worth $44,000 after acquiring an additional 483 shares during the last quarter. Quent Capital LLC purchased a new stake in shares of Cooper Companies during the third quarter worth approximately $44,000. Finally, Mather Group LLC. acquired a new position in Cooper Companies in the 3rd quarter valued at $56,000. 24.39% of the stock is owned by hedge funds and other institutional investors.

Cooper Companies Stock Up 0.5%

Shares of NASDAQ COO opened at $84.07 on Monday. The company has a 50 day simple moving average of $82.12 and a 200-day simple moving average of $75.30. The company has a market capitalization of $16.48 billion, a P/E ratio of 44.72, a P/E/G ratio of 2.40 and a beta of 1.03. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.89 and a quick ratio of 1.13. The Cooper Companies, Inc. has a 1 year low of $61.78 and a 1 year high of $92.84.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings data on Thursday, December 4th. The medical device company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.11 by $0.04. The firm had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.06 billion. Cooper Companies had a return on equity of 10.02% and a net margin of 9.16%.The firm’s quarterly revenue was up 4.6% on a year-over-year basis. During the same period in the prior year, the firm posted $1.04 earnings per share. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. On average, equities research analysts predict that The Cooper Companies, Inc. will post 3.98 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on COO shares. Mizuho set a $100.00 target price on shares of Cooper Companies and gave the stock an “outperform” rating in a research note on Friday, December 5th. Needham & Company LLC decreased their price target on shares of Cooper Companies from $100.00 to $99.00 and set a “buy” rating on the stock in a research note on Tuesday, February 3rd. The Goldman Sachs Group restated a “sell” rating and set a $73.00 price target on shares of Cooper Companies in a research report on Friday, January 9th. Stifel Nicolaus set a $95.00 price objective on shares of Cooper Companies and gave the company a “buy” rating in a report on Friday, December 5th. Finally, Weiss Ratings raised shares of Cooper Companies from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, January 12th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $90.77.

Insider Buying and Selling at Cooper Companies

In other Cooper Companies news, Director Maria Rivas acquired 1,000 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The stock was purchased at an average cost of $82.13 per share, with a total value of $82,130.00. Following the transaction, the director owned 11,141 shares of the company’s stock, valued at $915,010.33. This trade represents a 9.86% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Lawrence Erik Kurzius acquired 2,000 shares of Cooper Companies stock in a transaction that occurred on Wednesday, December 17th. The stock was bought at an average price of $82.50 per share, for a total transaction of $165,000.00. Following the completion of the acquisition, the director owned 7,777 shares in the company, valued at $641,602.50. This trade represents a 34.62% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders bought 16,014 shares of company stock worth $1,304,416. Insiders own 1.98% of the company’s stock.

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.